dc.contributor.author | Topuz, Erkan | |
dc.contributor.author | Tas, Faruk | |
dc.contributor.author | Derin, Duygu | |
dc.contributor.author | Guney, Nese | |
dc.contributor.author | Aydiner, Adnan | |
dc.date.accessioned | 2021-03-03T11:48:46Z | |
dc.date.available | 2021-03-03T11:48:46Z | |
dc.date.issued | 2008 | |
dc.identifier.citation | Tas F., Guney N., Derin D., Aydiner A., Topuz E., "A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.13, sa.2, ss.156-160, 2008 | |
dc.identifier.issn | 1341-9625 | |
dc.identifier.other | av_2a1c3435-5e75-449d-93d7-22ece3ce4347 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/33101 | |
dc.identifier.uri | https://doi.org/10.1007/s10147-007-0740-4 | |
dc.description.abstract | Background. Both gemcitabine and pegylated liposomal doxorubicin (PLD) are antineoplastic drugs with clinical activity in patients with platinum-resistant ovarian cancer. The present study was designed to assess the efficacy and safety of biweekly scheduled gemcitabine and PLD combination therapy in such patients. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Onkoloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer | |
dc.type | Makale | |
dc.relation.journal | INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | |
dc.contributor.department | İstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü | |
dc.identifier.volume | 13 | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | 156 | |
dc.identifier.endpage | 160 | |
dc.contributor.firstauthorID | 187067 | |